Tag: Benign Prostatic Hyperplasia Treatment Market

Categories
Business

Demand For Benign Prostatic Hyperplasia Prostate Treatment Is Predicted To Grow At A 5% CAGR From 2022-2032

The greatest market and commercial solutions are necessary to succeed in the quickly evolving marketplace. The comprehensive Benign Prostatic Hyperplasia Treatment market study also examines significant industry breakthroughs in light of the existing environment and anticipated future improvements. Additionally, this market report provides information on historical data, current market trends, the environment, technological innovation, upcoming technologies, and technical advancement in the relevant industry. All of this information helps the abc industry make better decisions to improve its strategy for trading goods and services. As a result, persuading Benign Prostatic Hyperplasia Treatment market research encourages organizations to concentrate on the market’s more crucial components.

The Benign Prostatic Hyperplasia Treatment market analysis study looks at key industry trends, market size, share projections, and sales volume to help companies determine how to maximize their return on investment (roi). Additionally, this research includes information about the manufacturer’s contact details, the production value of the products, and the company’s market shares. Businesses can learn about the tactics used by major market players, including but not limited to new product launches, product expansions, agreements, joint ventures, partnerships, and acquisitions, by studying competition analysis. Using methods and techniques like swot analysis and porter’s five forces analysis, all the data and information obtained for the report is examined and analyzed.

Download Free Sample Copy of this Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=4412

Key findings of the Benign Prostatic Hyperplasia Treatment market study:

  • The report provides a present market outlook on Benign Prostatic Hyperplasia Treatment. Additionally, the Benign Prostatic Hyperplasia Treatment market share is anticipated to grow with a CAGR of 5% in the forecast period.
  • Regional breakdown of the Benign Prostatic Hyperplasia Treatment market based on predefined taxonomy.
  • Innovative manufacturing processes implemented by Benign Prostatic Hyperplasia Treatment vendors in detail.
  • Region-wise and country-wise fragmentation of the Benign Prostatic Hyperplasia Treatment market to grasp the revenue, and growth outlook in these areas.
  • Changing preferences among consumers across various regions and countries.
  • Factors (Positive and Negative) impacting the growth of the global Benign Prostatic Hyperplasia Treatment market.
  • Benign Prostatic Hyperplasia Treatment price, market share, and Trends forecast for assessment period 2022-2032

Key Segments Profiled in the Benign Prostatic Hyperplasia Treatment Industry Survey

  • By Treatment :
    • Drug Class
      • Alpha Blockers
      • 5-Alpha-reductase Inhibitors (5-ARIs)
      • Phosphodiesterase-5 Enzyme Inhibitors
      • Others
    • Minimally-invasive Surgeries
      • Transurethral Resection of the Prostate (TURP)
      • Transurethral Incision of the Prostate (TUIP)
      • Robotic Surgeries
      • Transurethral Microwave Thermotherapy (TUMT)
      • Prostatic Urethral Lift
      • Others
    • Laser Therapy
    • Others
  • By End User :
    • Hospitals
    • Ambulatory Surgical Centres
    • Specialty Clinics
    • Others
  • By Region :
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East & Africa

Get Customization on this Report for Specific Country –  https://www.factmr.com/connectus/sample?flag=RC&rep_id=4412

What makes this Research different from others?

  • COVID- Impact analysis- The report includes details of the impact of the pandemic on the Benign Prostatic Hyperplasia Treatment market further including insights on the pre-COVID situation. Additionally, this report benefits in terms of post-COVID recovery prospects, changing consumer demands, and buying patterns valuable for Benign Prostatic Hyperplasia Treatment companies.
  • Industrial trend analysis- The research covers recent trends in the field of Benign Prostatic Hyperplasia Treatment which are augmented with the applicable technologies and shifts in industrial processes. The scope for digital and industrial technologies is discussed in order to help client firms to understand the benefits and risks included in light of market trends.
  • Benign Prostatic Hyperplasia Treatment Sustainability metrics- The rising concerns of environmentally friendly production and consumption are taken to next level in this research, as research is focused on emerging methods of ensuring sustainability. These insights include climate-friendly initiatives adopted by some players in the industry. Furthermore, details of manufacturers’ impact on carbon footprint are evaluated intend to make clients aware of their contribution to sustainable development goals.

Competitive Landscape

The Benign Prostatic Hyperplasia Treatment industry is dominated by some prominent players including

  • Abbott Laboratories
  • Allergan Plc.
  • Astellas Pharma Inc.
  • Asahi Kasei Corporation
  • Boehringer Ingelheim GmbH
  • GlaxoSmithKline Plc.
  • Pfizer Inc.
  • Boston Scientific Corporation
  • Teleflex Incorporated
  • Endo International Plc.
  • Urologix LLC
  • LISA Laser
  • Olympus Corporation
  • Teva Pharmaceutical Industries Ltd.
  • Merck & Co. Inc.

The competition in the sector is driven by key parameters such as product price, targeted customer base, and strategic marketing. Major players in the market focused on the Benign Prostatic Hyperplasia Treatment market innovation by investing more in research and development. Furthermore, the industry players are focusing on the extensive usage of online distribution channels for enhanced cost-effectiveness. The sustainability in the supply chain is a decisive factor for Benign Prostatic Hyperplasia Treatment brands leading to an impact on the margin profits of firms.

Report Benefits & Key Questions Answered

  • Benign Prostatic Hyperplasia Treatment Company & brand share analysis: Company and brand share analysis on Benign Prostatic Hyperplasia Treatment reveals how much market share is captured by Tier 1, Tier 2, and Tier 3 players
  • Benign Prostatic Hyperplasia Treatment Historical volume analysis: The industry analysis provides data & insights on historical volume sales of Benign Prostatic Hyperplasia Treatment
  • Benign Prostatic Hyperplasia Treatment Category & segment level analysis: Fact.MR’s Benign Prostatic Hyperplasia Treatment sales outlook offers category and segment level analysis on lucrative and nascent product types. Market players can use this information to identify sales potential and set sales targets at local, country, and regional level.
  • Benign Prostatic Hyperplasia Treatment Consumption by demographics: The market intelligence study provides consumption by demographics analysis so market players can design their product and marketing strategies on the basis of high-value consumers
  • Post COVID consumer spending on Benign Prostatic Hyperplasia Treatment: The report includes post COVID consumer spending analysis. This information will help business leads understand the shifts in purchasing power and behavior
  • Manufacturing trend analysis: Vital information on how market players are aligning their manufacturing strategies with respect to evolving consumer sentiments

Interested to Procure The Data? Inquire here at – https://www.factmr.com/checkout/4412

Contact:

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Email: sales@factmr.com

Categories
Pharmaceutical

Demand For Benign Prostatic Hyperplasia Treatment Market To Witness An Outstanding Growth By 2027 | Fact.MR Study

Benign Prostatic Hyperplasia Treatment Market Size, Trend Analysis & Competition Tracking By Drug Classes (Alpha Blockers, 5-Alpha-reductase Inhibitors (5-ARIs), Phosphodiesterase-5 Enzyme Inhibitors), By Minimally-invasive Surgeries, By Laser Therapy – Global Market Insights 

With a multi-disciplinary approach, Fact.MR elaborates an extensive analysis of the historical, current and future outlook of the global Benign Prostatic Hyperplasia Treatment as well as the factors responsible for such a growth. Our highly dedicated professionals have inputted critical and accurate insights associated with every industry, and region by doing thorough primary and secondary research.

We leverage space-age industrial and digitalization tools to provide avant-garde actionable insights to our clients regarding the Benign Prostatic Hyperplasia Treatment. For enhancing readers’ experience, the report starts with a basic overview about the Benign Prostatic Hyperplasia Treatment and its classification.

To remain ‘ahead’ of your competitors, request a sample:

https://www.factmr.com/connectus/sample?flag=S&rep_id=4412

Benign Prostatic Hyperplasia Market – Assessment of Key Segments

Authors of this comprehensive study have classified the BPH treatment market into key segments for an in-depth study of the market. Categorisation of the benign prostatic hyperplasia treatment market is based on treatment type, end user, and region. This detailed study also offers information about the incremental opportunities present in the benign prostatic hyperplasia treatment market during the forecast period. Key segments considered while studying the benign prostatic hyperplasia treatment market include:

Treatment Type
  • Drug Classes
    • Alpha Blockers
    • 5-Alpha-reductase Inhibitors (5-ARIs)
    • Phosphodiesterase-5 Enzyme Inhibitors
    • Others
  • Minimally-invasive Surgeries
    • Transurethral Resection of the Prostate (TURP)
    • Transurethral Incision of the Prostate (TUIP)
    • Robotic Surgeries
    • Transurethral Microwave Thermotherapy (TUMT)
    • Prostatic Urethral Lift
    • Others
  • Laser Therapy
  • Others
End User
  • Hospitals
  • Ambulatory Surgical Centres
  • Specialty Clinics
  • Others
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Speak To Research Analyst For Detailed Insights

https://www.factmr.com/connectus/sample?flag=AE&rep_id=4412

The insights for each vendor consists of:

  • Company profile
  • SWOT analysis
  • Main market information
  • Market share
  • Revenue, pricing and gross margin

What insights does the Benign Prostatic Hyperplasia Treatment Market report provide to the readers?

  • Benign Prostatic Hyperplasia Treatment fragmentation on the basis of product type, end use, and region.
  • Comprehensive assessment of upstream starting materials, downstream demand, and present market landscape.
  • Collaborations, R&D projects, acquisitions, and product launches of each Benign Prostatic Hyperplasia Treatment player.
  • Various regulations imposed by the governments on the consumption of Benign Prostatic Hyperplasia Treatment in detail.
  • Impact of modern technologies, such as big data & analytics, artificial intelligence, and social media platforms on the global Benign Prostatic Hyperplasia Treatment.

Full Access of this Report Is Available at

https://www.factmr.com/checkout/4412

The report covers following Benign Prostatic Hyperplasia Treatment Market insights and assessment that are helpful for all participants involved in the Benign Prostatic Hyperplasia Treatment market:

  • Data on recently introduced regulations and their impact on key industries and on demand in Benign Prostatic Hyperplasia Treatment
  • Latest industry Analysis on Benign Prostatic Hyperplasia Treatment Market, with key analysis of market drivers, trends, and influencing factors
  • Key trends Analysis of Benign Prostatic Hyperplasia Treatment Market and changing consumer preferences in major industries.
  • Changing Benign Prostatic Hyperplasia Treatment demand and consumption of diverse products
  • Major trends underlining funding by key investors in numerous countries
  • New investment opportunities in diverse technology and product or service types
  • Comprehensive data and Competitive analysis of Benign Prostatic Hyperplasia Treatment major players
  • Benign Prostatic Hyperplasia Treatment Market sales in US will grow at a steady pace, driven by growing consumer confidence and economic recovery
  • Benign Prostatic Hyperplasia Treatment demand forecast in Europe remains stable, as many countries such as UK, France, and Germany focus on boosting growth

Questionnaire answered in the Benign Prostatic Hyperplasia Treatment Market report include:

  • How the market for Benign Prostatic Hyperplasia Treatment has grown?
  • What is the present and future outlook of the global Benign Prostatic Hyperplasia Treatment on the basis of region?
  • What are the challenges and opportunities for the Benign Prostatic Hyperplasia Treatment?
  • Why the consumption of Benign Prostatic Hyperplasia Treatment highest in region?
  • In which year segment is expected to overtake segment?

Read Our Latest Article on Healthcare Domain 

https://www.factmr.com/article/124/latest-trends-in-the-healthcare-industry-how-has-it-transformed-businesses

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.

contact:

21st floor , 136 Sejong-daero,
Seoul,100-768
South Korea
Phone: +1 (628) 251-1583
Email: sales@factmr.com

Categories
Pharmaceutical

Nearly 50% of the Total Revenue in the Benign Prostatic Hyperplasia Laser Therapy Market is Projected to Arrive from Drug Classes by 2031 End

The market study done by Fact.MR gives exclusive information about how the market will grow. The study identifies crucial trends that are determining the growth of Benign Prostatic Hyperplasia Laser Therapy market. This newly published report sheds light on vital dynamics, such as the drivers, restraints, and opportunities for key market players as well as emerging players associated with the production and supply. The latest report by Fact.MR provides detailed Market Analysis of Benign Prostatic Hyperplasia Laser Therapy

The report offers actionable and valuable market insights of Benign Prostatic Hyperplasia Laser Therapy. The latest report by Fact.MR provides details on the present scenario of the market across various regions along with the historic data and forecast of the market. The report also includes information on the sales and demand of Benign Prostatic Hyperplasia Laser Therapy Market across various industries and regions.

To remain ‘ahead’ of your competitors, request for a sample –  https://www.factmr.com/connectus/sample?flag=S&rep_id=4412

This newly published and insightful report sheds light on Market Insights of Benign Prostatic Hyperplasia Laser Therapy, key dynamics, their impact on the overall value chain from suppliers to end-users and Growth of Benign Prostatic Hyperplasia Laser Therapy Market.

An exhaustive study published by Fact.MR finds that, transurethral resection of prostate (TURP) surgery is expected to contribute around 30% of market share by 2027, as it is proving highly-effective over drugs for the treatment of benign prostatic hyperplasia (BPH). High success rate of the TURP surgery is encouraging market players to further explore advanced technologies and increase surgical precision. On account of technological leaps, robotic surgery and laser therapy are the most recent breakthroughs in the benign prostatic hyperplasia treatment market, which are being fast-adopted by medical professionals to relieve the symptoms of BPH.

However, these high-end therapeutics are currently not under the ambit of insurance, resulting in high out-of-pocket spending for patients. To sum it all, the study expects moderate growth of the benign prostatic hyperplasia treatment market during the forecast period (2020-2027).

Key Highlights of Benign Prostatic Hyperplasia Treatment Market Study

  • Hospitals will remain key treatment centres, with over 40% revenue contribution to the BPH treatment market during 2020-2027. However, expensiveness of TURP surgeries, lengthy procedures, and long stays in hospitals are diverting patients’ inclination towards specialty clinics.
  • Manufacturers continue to extend efforts towards enhancing product efficacy, which is strengthening the pipeline for BPH treatment with numerous inhibitors and immunotherapies in phase II and phase III trials. This signifies a sustainable supply of branded therapeutics during the forecast period.
  • The U.S. is projected to account for around 25% of the global BPH treatment market share during 2020-2027, as regional manufacturers gain the early-slice of technology to foster innovation. However, India is projected to grow at the highest rate in the benign prostatic hyperplasia treatment market, on account of relatively low BPH treatment costs that attract a large number of medical tourists.
  • Loss of patent exclusivity of branded drugs is increasing the availability of generic drugs, which prevents the benign prostatic hyperplasia treatment market from reaching its true revenue potential.

A senior consultant at Fact.MR opines,“Manufacturers can target expansions in India and China, as relatively low setup and labour costs would result in reduced price of products, and, in turn, improve the adoption rate of otherwise expensive therapeutics. Also, a large geriatric population in Japan and high prevalence of BPH among men over 50 years are likely to increase market opportunities in this country.”

Need more information about Report Methodology? Click here-  https://www.factmr.com/connectus/sample?flag=RM&rep_id=4412

Switch from Rx to OTC Drug Status to Remain Crucial for Leading Players to Improve Sales Prospects

Olympus, Teleflex, and Boston Scientific Corporation hold significant share tantamount to 58% in the global benign prostatic hyperplasia treatment market. These leading players have high focus on R&D activities to increase the exclusivity of products and strengthen the pipeline of branded drugs. However, frequent instances of patent expiration are opening market opportunities for prominent and emerging players, who develop generic drugs and biosimilar products.

Low costs of generic drugs as compared to branded ones are creating a wide base of consumers for this drug category. However, the same takes a toll on the market value of branded drugs, which is turning into a concern for leading market players. To offset this challenge, leading manufacturers are changing the status of their branded drugs from prescription-based drugs to OTC to achieve high adoption of their products.

Benign Prostatic Hyperplasia Market – Assessment of Key Segments

Authors of this comprehensive study have classified the BPH treatment market into key segments for an in-depth study of the market. Categorisation of the benign prostatic hyperplasia treatment market is based on treatment type, end user, and region. This detailed study also offers information about the incremental opportunities present in the benign prostatic hyperplasia treatment market during the forecast period. Key segments considered while studying the benign prostatic hyperplasia treatment market include:

Treatment Type
  • Drug Classes
    • Alpha Blockers
    • 5-Alpha-reductase Inhibitors (5-ARIs)
    • Phosphodiesterase-5 Enzyme Inhibitors
    • Others
  • Minimally-invasive Surgeries
    • Transurethral Resection of the Prostate (TURP)
    • Transurethral Incision of the Prostate (TUIP)
    • Robotic Surgeries
    • Transurethral Microwave Thermotherapy (TUMT)
    • Prostatic Urethral Lift
    • Others
  • Laser Therapy
  • Others
End User
  • Hospitals
  • Ambulatory Surgical Centres
  • Specialty Clinics
  • Others
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Full Access of this Exclusive Report is Available at-  https://www.factmr.com/checkout/4412

Key Question answered in the survey of Benign Prostatic Hyperplasia Laser Therapy market report:

  • Sales and Demand of Benign Prostatic Hyperplasia Laser Therapy
  • Growth of Benign Prostatic Hyperplasia Laser Therapy Market
  • Market Analysis of Benign Prostatic Hyperplasia Laser Therapy
  • Market Insights of Benign Prostatic Hyperplasia Laser Therapy
  • Key Drivers Impacting the Benign Prostatic Hyperplasia Laser Therapy market
  • Which are the Key drivers impacted by Benign Prostatic Hyperplasia Laser Therapy market
  • Restraints Shaping Market Growth
  • Market Survey of Benign Prostatic Hyperplasia Laser Therapy

growth potential of benign prostatic hyperplasia treatment market by treatment
More Valuable Insights on Benign Prostatic Hyperplasia Laser Therapy Market

Fact.MR, in its new report, offers an unbiased Market Analysis of Benign Prostatic Hyperplasia Laser Therapy, Sales and Demand of Benign Prostatic Hyperplasia Laser Therapy, analyzing forecast statistics through 2019 and beyond. The study reveals growth projections on the basis of various criteria.

Explore Fact.MR’s Comprehensive Coverage on Healthcare Domain:

Fluoro Enzymatic Assays Market – Global Industry Analysis and Opportunity Assessment 2021 – 2031

Shower Chairs Market – Global Industry Analysis and Opportunity Assessment 2021 – 2031

Infrared Thermometer Market – Global Industry Analysis and Opportunity Assessment 2021 – 2031

Read More Trending Reports of Fact.MR-

https://www.biospace.com/article/demand-for-tricuspid-valve-repair-rising-as-congenital-and-rheumatoid-heart-disease-cases-increase-fact-mr/

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.

Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Email: sales@factmr.com
Visit Our Website: https://www.factmr.com

Categories
Pharmaceutical

Loss of Patent Exclusivity Creating Lucrative Ground for Generic Drugs in Benign Prostatic Hyperplasia Treatment Market

An exhaustive study published by Fact.MR finds that, transurethral resection of prostate (TURP) surgery is expected to contribute around 30% of market share by 2027, as it is proving highly-effective over drugs for the treatment of benign prostatic hyperplasia (BPH). High success rate of the TURP surgery is encouraging market players to further explore advanced technologies and increase surgical precision. On account of technological leaps, robotic surgery and laser therapy are the most recent breakthroughs in the benign prostatic hyperplasia treatment market, which are being fast-adopted by medical professionals to relieve the symptoms of BPH.

For detailed insights on enhancing your product footprint, request for a sample here – https://www.factmr.com/connectus/sample?flag=S&rep_id=4412

However, these high-end therapeutics are currently not under the ambit of insurance, resulting in high out-of-pocket spending for patients. To sum it all, the study expects moderate growth of the benign prostatic hyperplasia treatment market during the forecast period (2020-2027).

growth potential of benign prostatic hyperplasia treatment market by treatment

Key Highlights of Benign Prostatic Hyperplasia Treatment Market Study

  • Hospitals will remain key treatment centres, with over 40% revenue contribution to the BPH treatment market during 2020-2027. However, expensiveness of TURP surgeries, lengthy procedures, and long stays in hospitals are diverting patients’ inclination towards specialty clinics.
  • Manufacturers continue to extend efforts towards enhancing product efficacy, which is strengthening the pipeline for BPH treatment with numerous inhibitors and immunotherapies in phase II and phase III trials. This signifies a sustainable supply of branded therapeutics during the forecast period.

For critical insights on this market, request for methodology here – https://www.factmr.com/connectus/sample?flag=RM&rep_id=4412

  • The U.S. is projected to account for around 25% of the global BPH treatment market share during 2020-2027, as regional manufacturers gain the early-slice of technology to foster innovation. However, India is projected to grow at the highest rate in the benign prostatic hyperplasia treatment market, on account of relatively low BPH treatment costs that attract a large number of medical tourists.
  • Loss of patent exclusivity of branded drugs is increasing the availability of generic drugs, which prevents the benign prostatic hyperplasia treatment market from reaching its true revenue potential.

A senior consultant at Fact.MR opines, “Manufacturers can target expansions in India and China, as relatively low setup and labour costs would result in reduced price of products, and, in turn, improve the adoption rate of otherwise expensive therapeutics. Also, a large geriatric population in Japan and high prevalence of BPH among men over 50 years are likely to increase market opportunities in this country.”

For in-depth competitive analysis, buy now – https://www.factmr.com/checkout/4412

Switch from Rx to OTC Drug Status to Remain Crucial for Leading Players to Improve Sales Prospects

Olympus, Teleflex, and Boston Scientific Corporation hold significant share tantamount to 58% in the global benign prostatic hyperplasia treatment market. These leading players have high focus on R&D activities to increase the exclusivity of products and strengthen the pipeline of branded drugs.

However, frequent instances of patent expiration are opening market opportunities for prominent and emerging players, who develop generic drugs and biosimilar products. Low costs of generic drugs as compared to branded ones are creating a wide base of consumers for this drug category. However, the same takes a toll on the market value of branded drugs, which is turning into a concern for leading market players. To offset this challenge, leading manufacturers are changing the status of their branded drugs from prescription-based drugs to OTC to achieve high adoption of their products.

Read More Trending and Similar Reports from Fact.MR – http://www.globenewswire.com/en/news-release/2018/08/08/1549081/0/en/Orthopedic-Implants-Market-Sales-in-Knee-Reconstruction-Pre-eminent-Hip-Reconstruction-to-Gain-Steady-Momentum-slates-Fact-MR.html

Explore Fact.MR’s Comprehensive Coverage on Healthcare Landscape

Lung Management Products Market Forecast, Trend Analysis & Competition Tracking-Global Market Insights 2018 to 2028- https://www.factmr.com/report/2030/lung-management-products-market

Primary Hyperoxaluria Treatment Market Forecast, Trend Analysis, & Competition Tracking – Global Market Insights 2020 to 2030- https://www.factmr.com/report/5257/primary-hyperoxaluria-treatment-market

Surgical AR Systems Market Forecast, Trend Analysis, & Competition Tracking – Global Review 2020 to 2030- https://www.factmr.com/report/5258/surgical-ar-systems-market

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.

Contact:

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Email: sales@factmr.com
Visit Our Website: https://www.factmr.com

Categories
Pharmaceutical

Benign Prostatic Hyperplasia Laser Therapy An Insight On the Important Factors and Trends Influencing the Market

The market study done by Fact.MR gives exclusive information about how the market will grow. The study identifies crucial trends that are determining the growth of Benign Prostatic Hyperplasia Laser Therapy market. This newly published report sheds light on vital dynamics, such as the drivers, restraints, and opportunities for key market players as well as emerging players associated with the production and supply. The latest report by Fact.MR provides detailed Market Analysis of Benign Prostatic Hyperplasia Laser Therapy

The report offers actionable and valuable market insights of Benign Prostatic Hyperplasia Laser Therapy. The latest report by Fact.MR provides details on the present scenario of the market across various regions along with the historic data and forecast of the market. The report also includes information on the sales and demand of Benign Prostatic Hyperplasia Laser Therapy Market across various industries and regions.

To remain ‘ahead’ of your competitors, request for a sample –  https://www.factmr.com/connectus/sample?flag=S&rep_id=4412

This newly published and insightful report sheds light on Market Insights of Benign Prostatic Hyperplasia Laser Therapy, key dynamics, their impact on the overall value chain from suppliers to end-users and Growth of Benign Prostatic Hyperplasia Laser Therapy Market.

An exhaustive study published by Fact.MR finds that, transurethral resection of prostate (TURP) surgery is expected to contribute around 30% of market share by 2027, as it is proving highly-effective over drugs for the treatment of benign prostatic hyperplasia (BPH). High success rate of the TURP surgery is encouraging market players to further explore advanced technologies and increase surgical precision. On account of technological leaps, robotic surgery and laser therapy are the most recent breakthroughs in the benign prostatic hyperplasia treatment market, which are being fast-adopted by medical professionals to relieve the symptoms of BPH.

However, these high-end therapeutics are currently not under the ambit of insurance, resulting in high out-of-pocket spending for patients. To sum it all, the study expects moderate growth of the benign prostatic hyperplasia treatment market during the forecast period (2020-2027).

Need more information about Report Methodology? Click here-  https://www.factmr.com/connectus/sample?flag=RM&rep_id=4412

Key Highlights of Benign Prostatic Hyperplasia Treatment Market Study

  • Hospitals will remain key treatment centres, with over 40% revenue contribution to the BPH treatment market during 2020-2027. However, expensiveness of TURP surgeries, lengthy procedures, and long stays in hospitals are diverting patients’ inclination towards specialty clinics.
  • Manufacturers continue to extend efforts towards enhancing product efficacy, which is strengthening the pipeline for BPH treatment with numerous inhibitors and immunotherapies in phase II and phase III trials. This signifies a sustainable supply of branded therapeutics during the forecast period.
  • The U.S. is projected to account for around 25% of the global BPH treatment market share during 2020-2027, as regional manufacturers gain the early-slice of technology to foster innovation. However, India is projected to grow at the highest rate in the benign prostatic hyperplasia treatment market, on account of relatively low BPH treatment costs that attract a large number of medical tourists.
  • Loss of patent exclusivity of branded drugs is increasing the availability of generic drugs, which prevents the benign prostatic hyperplasia treatment market from reaching its true revenue potential.

A senior consultant at Fact.MR opines,“Manufacturers can target expansions in India and China, as relatively low setup and labour costs would result in reduced price of products, and, in turn, improve the adoption rate of otherwise expensive therapeutics. Also, a large geriatric population in Japan and high prevalence of BPH among men over 50 years are likely to increase market opportunities in this country.”

Switch from Rx to OTC Drug Status to Remain Crucial for Leading Players to Improve Sales Prospects

Olympus, Teleflex, and Boston Scientific Corporation hold significant share tantamount to 58% in the global benign prostatic hyperplasia treatment market. These leading players have high focus on R&D activities to increase the exclusivity of products and strengthen the pipeline of branded drugs. However, frequent instances of patent expiration are opening market opportunities for prominent and emerging players, who develop generic drugs and biosimilar products.

Low costs of generic drugs as compared to branded ones are creating a wide base of consumers for this drug category. However, the same takes a toll on the market value of branded drugs, which is turning into a concern for leading market players. To offset this challenge, leading manufacturers are changing the status of their branded drugs from prescription-based drugs to OTC to achieve high adoption of their products.

Benign Prostatic Hyperplasia Market – Assessment of Key Segments

Authors of this comprehensive study have classified the BPH treatment market into key segments for an in-depth study of the market. Categorisation of the benign prostatic hyperplasia treatment market is based on treatment type, end user, and region. This detailed study also offers information about the incremental opportunities present in the benign prostatic hyperplasia treatment market during the forecast period. Key segments considered while studying the benign prostatic hyperplasia treatment market include:

Treatment Type
  • Drug Classes
    • Alpha Blockers
    • 5-Alpha-reductase Inhibitors (5-ARIs)
    • Phosphodiesterase-5 Enzyme Inhibitors
    • Others
  • Minimally-invasive Surgeries
    • Transurethral Resection of the Prostate (TURP)
    • Transurethral Incision of the Prostate (TUIP)
    • Robotic Surgeries
    • Transurethral Microwave Thermotherapy (TUMT)
    • Prostatic Urethral Lift
    • Others
  • Laser Therapy
  • Others
End User
  • Hospitals
  • Ambulatory Surgical Centres
  • Specialty Clinics
  • Others
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Full Access of this Exclusive Report is Available at-  https://www.factmr.com/checkout/4412

Key Question answered in the survey of Benign Prostatic Hyperplasia Laser Therapy market report:

  • Sales and Demand of Benign Prostatic Hyperplasia Laser Therapy
  • Growth of Benign Prostatic Hyperplasia Laser Therapy Market
  • Market Analysis of Benign Prostatic Hyperplasia Laser Therapy
  • Market Insights of Benign Prostatic Hyperplasia Laser Therapy
  • Key Drivers Impacting the Benign Prostatic Hyperplasia Laser Therapy market
  • Which are the Key drivers impacted by Benign Prostatic Hyperplasia Laser Therapy market
  • Restraints Shaping Market Growth
  • Market Survey of Benign Prostatic Hyperplasia Laser Therapy

growth potential of benign prostatic hyperplasia treatment market by treatment
More Valuable Insights on Benign Prostatic Hyperplasia Laser Therapy Market

Fact.MR, in its new report, offers an unbiased Market Analysis of Benign Prostatic Hyperplasia Laser Therapy, Sales and Demand of Benign Prostatic Hyperplasia Laser Therapy, analyzing forecast statistics through 2019 and beyond. The study reveals growth projections on the basis of various criteria.

Sodium Formate Industry Survey Report by Fact.MR – https://www.youtube.com/watch?v=MuydFhdcGdA

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.

Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Email: sales@factmr.com
Visit Our Website: https://www.factmr.com